Thyroid Cancer 101: A Variant of Papillary Cancer Which is Now not a Cancer.
- 1/6 of all papillary cancers in the past are now not cancers.
- Example of a NIFT-P diagnosed by a lobe removal. She was told it looked like cancer but was a look a like benign tumor requiring no cancer treatment of long term follow up.
- Redefining noninvasive follicular variant of papillary thyroid carcinoma as a neoplasm rather than a carcinoma is called non-invasive follicular tumor with papillary look a like cells NFTP.
- What does it mean for patients with papillary thyroid cancer?
- NIFT-P is not cancer!
- A out of network second opinion should help you decide if you do not have cancer but a benign follicular tumor instead.
- If you have NIFT-P you may not need a total thyroid removal but either just a lobe to confirm it is benign.
- NIFT-P patients after diagnosis can be spared the long term expense of radiation, imaging, and testing for years.
- Your insurance will not be effected by a cancer diagnosis.
- Markers and advanced cytology methods can in the future diagnose NIFT-P without surgery.
Call me for a second opinion before surgery.You may not have cancer but this look a like benign tumor instead. 31-393-8860 or email to email@example.com.
Recent discussions have focused on redefining noninvasive follicular variant of papillary thyroid carcinoma (NI‐FVPTC) as a neoplasm rather than a carcinoma. This study assesses the potential impact of such a reclassification on the implied risk of malignancy (ROM) for the diagnostic categories of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC).
The study consisted of consecutive fine‐needle aspiration biopsy (FNAB) cases collected between January 1, 2013 and June 30, 2014 from 5 academic institutions. Demographic information, cytology diagnoses, and surgical pathology follow‐up were recorded. The ROM was calculated with and without NI‐FVPTC and was presented as a range: all cases (ie, overall risk of malignancy [OROM]) versus those with surgical follow‐up only.
The FNAB cohort consisted of 6943 thyroid nodules representing 5179 women and 1409 men with an average age of 54 years (range, 9‐94 years). The combined average ROM and OROM for the diagnostic categories of TBSRTC were as follows: nondiagnostic, 4.4% to 25.3%; benign, 0.9% to 9.3%; atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS), 12.1% to 31.2%; follicular neoplasm (FN), 21.8% to 33.2%; suspicious for malignancy (SM), 62.1% to 82.6%; and malignant, 75.9% to 99.1%. The impact of reclassifying NI‐FVPTC on the ROM and OROM was most pronounced and statistically significant in the 3 indeterminate categories: the AUS/FLUS category had a decrease of 5.2% to 13.6%, the FN category had a decrease of 9.9% to 15.1%, and the SM category had a decrease of 17.6% to 23.4% (P < .05), whereas the benign and malignant categories had decreases of 0.3% to 3.5% and 2.5% to 3.3%, respectfully. The trend of the effect on the ROM and OROM was similar for all 5 institutions.
The results from this multi‐institutional cohort indicate that the reclassification of NI‐FVPTC will have a significant impact on the ROM for the 3 indeterminate categories of TBSRTC. Cancer Cytopathol 2016;124:181–187. © 2015 American Cancer Society.